Healthcare · Biotechnology
Price
$31.50
Market Cap
$3.9B
Employees
181
Beta
0.74
Avg Volume
2,210,762
CEO
Richard John Daly
Business Description
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Business History
Price Overview
Last updated: Jun 27, 2026 11:02am (just now)$31.50
+0.08 (+0.25%)
Day Range
$31.41 – $31.50
52-Week Range
$19.05 – $32.56
50-Day MA
$30.28
200-Day MA
$24.72
Volume
3,664,263.00
Analyst Price Targets
Low
$31.50
Consensus
$31.75
High
$32.00
(12 analysts)
Share Structure
Outstanding
122,419,767.00
Float
115,581,504.00
Free Float
94.4%
High free float
— 94.4% of shares trade freely, ~5.6% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
17.40
Stock Price: $31.50
EPS (Diluted): 1.75
EPS (Diluted): 1.75
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.99
Stock Price: $31.50
Total Equity: $954.27M
Shares: 127,257,929
Total Equity: $954.27M
Shares: 127,257,929
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
9.27
Market Cap: $3.86B
Total Debt: $437,000
Cash: $709.17M
EBITDA: $321.39M
Total Debt: $437,000
Cash: $709.17M
EBITDA: $321.39M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$2.1B
Market Cap: $3.86B
Total Debt: $437,000
Cash: $709.17M
Total Debt: $437,000
Cash: $709.17M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
85.2%
Gross Profit: $501.74M
Revenue: $588.99M
Revenue: $588.99M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
43.8%
Operating Income: $257.78M
Revenue: $588.99M
Revenue: $588.99M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
36.4%
Net Income: $214.33M
Revenue: $588.99M
Revenue: $588.99M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
23.7%
Net Income: $214.33M
Total Equity: $954.27M
Total Equity: $954.27M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
19.7%
Operating Income: $257.78M
Tax Rate: 24.4%
Equity: $954.27M
Total Debt: $437,000
Cash: $709.17M
Tax Rate: 24.4%
Equity: $954.27M
Total Debt: $437,000
Cash: $709.17M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
6.08
Current Assets: $894.03M
Current Liabilities: $147.15M
Current Liabilities: $147.15M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $437,000
Long-Term Debt: $0.00
Total Debt: $437,000
Total Equity: $954.27M
Long-Term Debt: $0.00
Total Debt: $437,000
Total Equity: $954.27M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$4.63
Revenue: $588.99M
Shares: 127,257,929
Shares: 127,257,929
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$7.50
Total Equity: $954.27M
Shares: 127,257,929
Shares: 127,257,929
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$1.64
Operating CF: $208.67M
CapEx: -$58,000
Shares: 127,257,929
CapEx: -$58,000
Shares: 127,257,929
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $31.50
Stock Price: $31.50
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $214.33M
Net Income: $214.33M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CPRX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $140.8M | $214.2M | $398.2M | $491.7M | $589.0M |
| Cost of Revenue | $21.9M | $34.4M | $52.0M | $68.8M | $87.3M |
| Gross Profit | $118.9M | $179.8M | $346.2M | $422.9M | $501.7M |
| Operating Expenses | $66.6M | $78.0M | $259.4M | $227.8M | $244.0M |
| Operating Income | $52.4M | $101.8M | $86.8M | $195.1M | $257.8M |
| Net Income | $39.5M | $83.1M | $71.4M | $163.9M | $214.3M |
| EBITDA | $52.9M | $106.0M | $127.4M | $254.0M | $321.4M |
| EPS | $0.38 | $0.80 | $0.67 | $1.38 | $1.75 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $171.4M | $298.4M | $137.6M | $517.6M | $709.2M |
| Total Current Assets | $210.1M | $320.8M | $219.3M | $623.6M | $894.0M |
| Total Assets | $237.8M | $375.6M | $470.1M | $851.4M | $1.1B |
| Current Liabilities | $27.1M | $57.6M | $76.1M | $120.7M | $147.2M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $31.0M | $75.2M | $82.2M | $123.8M | $152.5M |
| Total Equity | $206.8M | $300.4M | $387.9M | $727.6M | $954.3M |
| Retained Earnings | -$26.3M | $49.9M | $121.3M | $285.2M | $474.2M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $60.4M | $116.0M | $143.6M | $239.8M | $208.7M |
| Capital Expenditure | -$1.0M | $-29,000 | -$81.7M | $-556,000 | $-58,000 |
| Free Cash Flow | $59.4M | $116.0M | $61.9M | $239.3M | $208.6M |
| Acquisitions (net) | $0 | $10.0M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$12.1M | -$6.9M | $0 | $-296,000 | -$25.3M |
| Net Change in Cash | $41.2M | $127.0M | -$160.8M | $379.9M | $191.6M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 1:06am (9h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$717.9M $698.6M – $733.1M
|
$792.2M $778.9M – $801.8M
|
$877.4M $862.7M – $888.0M
|
$930.1M $914.5M – $941.4M
|
| EBITDA |
$323.4M $314.7M – $330.2M
|
$356.8M $350.8M – $361.1M
|
$395.2M $388.6M – $400.0M
|
$419.0M $411.9M – $424.1M
|
| Net Income |
$316.2M $268.9M – $331.5M
|
$327.3M $321.2M – $333.5M
|
$347.4M $339.8M – $352.9M
|
$347.4M $339.8M – $352.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:40pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +52.1% | +85.9% | +23.5% | +19.8% |
| Gross Profit Growth | +51.2% | +92.6% | +22.1% | +18.6% |
| Operating Income Growth | +94.4% | -14.8% | +124.8% | +32.1% |
| Net Income Growth | +110.4% | -14.0% | +129.5% | +30.8% |
| EBITDA Growth | +100.5% | +20.2% | +99.4% | +26.5% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-06-03 | Andrews William T. | M-Exempt | 3,052.00 | $0.00 | $0 |
| 2026-06-03 | Andrews William T. | M-Exempt | 3,052.00 | $0.00 | $0 |
| 2026-06-03 | Andrews William T. | F-InKind | 743.00 | $0.00 | $0 |
| 2026-02-17 | Russo Gregg | M-Exempt | 687.00 | $0.00 | $0 |
| 2026-02-17 | Russo Gregg | M-Exempt | 687.00 | $0.00 | $0 |
| 2026-02-17 | Russo Gregg | F-InKind | 211.00 | $0.00 | $0 |
| 2026-01-05 | Kalb Michael Wayne | M-Exempt | 7,139.00 | $0.00 | $0 |
| 2026-01-05 | Kalb Michael Wayne | M-Exempt | 7,139.00 | $0.00 | $0 |
| 2026-01-05 | Kalb Michael Wayne | F-InKind | 2,080.00 | $0.00 | $0 |
| 2026-01-05 | Daly Richard J | M-Exempt | 42,105.00 | $0.00 | $0 |
| 2026-01-05 | Daly Richard J | M-Exempt | 42,105.00 | $0.00 | $0 |
| 2026-01-05 | Daly Richard J | F-InKind | 10,577.00 | $0.00 | $0 |
| 2025-12-29 | DENKHAUS DONALD A | M-Exempt | 1,334.00 | $0.00 | $0 |
| 2025-12-29 | DENKHAUS DONALD A | M-Exempt | 1,334.00 | $0.00 | $0 |
| 2025-12-29 | Elsbernd Brian | M-Exempt | 6,667.00 | $0.00 | $0 |
| 2025-12-29 | Elsbernd Brian | M-Exempt | 6,667.00 | $0.00 | $0 |
| 2025-12-29 | Elsbernd Brian | F-InKind | 2,623.00 | $0.00 | $0 |
| 2025-12-29 | Tierney David S | M-Exempt | 1,334.00 | $0.00 | $0 |
| 2025-12-29 | Tierney David S | M-Exempt | 1,334.00 | $0.00 | $0 |
| 2025-12-29 | Sundaram Preethi | M-Exempt | 6,667.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CPRX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CPRX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30